NZYM B Novozymes A/S Class B

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook.

The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter.

Ester Baiget, President & CEO, says:

“We started the year with strong sales growth and earnings. This is a testament to our innovative solutions, resilient global business model, and our ability to continue to meet the increasing demand for biosolutions in an ever-changing world.”

“Emerging markets were a key growth driver, and all our four sales areas grew by double digits. We’re pleased with our progress, and we maintain our full-year financial outlook.”

“Overall, our Q1 performance underscores the value of our solutions in helping customers do more with less—enabling higher yields, improved throughput, enhanced performance, and greater benefits. And it shows that growth and planet stewardship can be two sides of the same coin.”

During the first three months of the financial year, Novonesis launched six innovations including an advanced protease portfolio for swift and efficient stain removal.

Divisional sales performance organic

In the first three months of the financial year, Food & Health Biosolutions grew by 12%, while Planetary Health Biosolutions grew by 11%. 

In Food & Health Biosolutions, Food & Beverages grew by 11% with double-digit growth across most categories. In Human Health, organic sales growth was 13% driven by a strong development in Dietary Supplements.

In Planetary Health Biosolutions, Household Care grew by 12%. The strong performance was driven by increased penetration and innovation. Agriculture, Energy & Tech grew by 10% driven by double-digit growth in Energy and Tech.

Regional performance organic

For the first quarter, emerging markets grew by 15% driven by all sales areas. Developed markets grew by 9%, driven by innovation.

For Q1 2025, organic growth rates by geography were 14% in Europe, Middle East & Africa, 7% in North America, 9% in Asia Pacific, and 18% in Latin America.

Outlook for 2025

The 2025 outlook is maintained at 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds.

The 2025 outlook is based on current levels of global trade tariffs. Our strong global setup, including flexible regional production capabilities, creates a diversified and resilient business. Additionally, we have confidence in passing on incremental cost driven by tariffs. As a result, we expect no or only marginal net impact from tariffs.

Financial calendar 2025 / 2026

  • August 21, 2025: H1 2025 financial results
  • November 6, 2025: Q3 2025 financial results
  • February 25, 2026: Full-year financial statement 2025
Media Relations  Investor Relations
Anne Sophie Scavenius

Senior Media Relations Manager

Phone:





 
  Tobias Cornelius Björklund

Head of Investor Relations

Phone:

Attachments



EN
08/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE

Biosolutions could create more than 600,000 jobs and unlock hundreds o...

Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe Biosolutions could create more than 600,000 jobs and unlock hundreds of billions in growth for Europe A new report reveals that biosolutions could generate EUR 133 billion in economic gains and create over 600,000 jobs across all of Europe by 2035. But without urgent policy leadership and better regulation, Europe risks becoming the world’s best lab for solutions that scale elsewhere. Copenhagen, Denmark – 7 July 2025: Europe is on the verge of a job and growth boom if bio...

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated  1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Please read the full announcement in PDF. Attachment

 PRESS RELEASE

Transactions under Novonesis’ share buyback program

Transactions under Novonesis’ share buyback program As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million (DKK 746 million) in total during the remainder of 2025. Please read the full announcement in PDF  Attachment

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 19, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,343,678 shares, corresponding to 4.98% (previously 5.02%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...

 PRESS RELEASE

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch